Anticoagulation therapy is prescribed for the prevention of recurrence of venous thromboembolism (VTE) in patients which could be temporarily paused during invasive procedures.
The COMMAN VTE registry is a multicenter registry with 3027 consecutive patients with acute symptomatic VTE in Japan between January 2010 and August 2014.
At a median follow-up period of 1213 (IQR: 847-1764) days, a total of 518 patients underwent invasive procedures with the cumulative incidences of 5.8% at 3 months, 11.1% at 1 year, and 24.0% at 5 years. A total of 382 patients were at high bleeding-risk category of invasive procedures. Out of this, anticoagulation therapy had been discontinued already in 62 patients (16%) and interrupted temporarily in 31 patients (39%) during invasive procedure with bridging anticoagulation therapy with heparin in 17 patients (21%). During a follow-up of 30 days following the invasive procedures, 14 patients (2.7%) experienced recurrent VTE and 28 patients (5.4%) had major bleeding.
This study explained the features of peri-procedural management and prognosis in patients with VTE following invasive procedures during follow-up in the large multicenter VTE registry. The incidence rates of recurrent VTE and major bleeding events at 30 days were 2.7% and 5.4%.